A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
Clinical trial NCT06905197 · RECRUITING
Trial details
- NCT number
- NCT06905197
- Sponsor
- Dizal Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-13
- Primary completion
- 2027-09-01
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.